92% of HF10 therapy trial patients report lowered back and leg pain — 5 things to know

Spinal Tech

The HF10 therapy trial, which is being administered by Alexander Hersel, MD, and Bradley Spiegel, MD, of Thousand Oaks, Calif.-based Management & Injury Relief Medical Center, has had encouraging results.

Here are five details:


1. The therapy is FDA approved and backed by 24-month clinical data that has proven its positive effects on patients suffering from low back and leg pain.


2. In 2016, 92 percent of HF10 Therapy's trial patients showed more increased pain relief and subsequently decided to move forward with the permanent implant.


3. Of the patients who opted for the permanent implant, 84 percent have sustained pain relief and improvements in function. Many have also reported a decrease in their dependency on pain medications.


4. The device is considered a form of neuromodulation, which is a type of therapy that rebalances neural circuits' activity in order to reduce pain symptoms.


5. Dr. Spiegel explains, "The device is very small and easy to implant during an outpatient surgical procedure."


More device-related articles:
ReMAP cleared to market 7D — 5 details

Medacta acquires Vivamed: 5 key notes

FDA reclassifies pedicle screws & clarifies dynamic stabilization systems

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers